11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Retinal pathological features and proteome signatures of Alzheimer’s disease

      research-article
      1 , 1 , 1 , 1 , 1 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 1 , 9 , 10 , 10 , 11 , 12 , 13 , 14 , 14 , 15 , 16 , 17 , 1 , 18 , 18 , 14 , 1 , 1 , 10 ,
      Acta Neuropathologica
      Springer Berlin Heidelberg
      Ocular abnormalities, Eye, Neurodegenerative disorders, S100β, GFAP, IBA1, scFvA13-intraneuronal oligomers, Immune responses

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alzheimer’s disease (AD) pathologies were discovered in the accessible neurosensory retina. However, their exact nature and topographical distribution, particularly in the early stages of functional impairment, and how they relate to disease progression in the brain remain largely unknown. To better understand the pathological features of AD in the retina, we conducted an extensive histopathological and biochemical investigation of postmortem retina and brain tissues from 86 human donors. Quantitative examination of superior and inferior temporal retinas from mild cognitive impairment (MCI) and AD patients compared to those with normal cognition (NC) revealed significant increases in amyloid β-protein (Aβ 42) forms and novel intraneuronal Aβ oligomers (AβOi), which were closely associated with exacerbated retinal macrogliosis, microgliosis, and tissue atrophy. These pathologies were unevenly distributed across retinal layers and geometrical areas, with the inner layers and peripheral subregions exhibiting most pronounced accumulations in the MCI and AD versus NC retinas. While microgliosis was increased in the retina of these patients, the proportion of microglial cells engaging in Aβ uptake was reduced. Female AD patients exhibited higher levels of retinal microgliosis than males. Notably, retinal Aβ 42, S100 calcium-binding protein B + macrogliosis, and atrophy correlated with severity of brain Aβ pathology, tauopathy, and atrophy, and most retinal pathologies reflected Braak staging. All retinal biomarkers correlated with the cognitive scores, with retinal Aβ 42, far-peripheral AβOi and microgliosis displaying the strongest correlations. Proteomic analysis of AD retinas revealed activation of specific inflammatory and neurodegenerative processes and inhibition of oxidative phosphorylation/mitochondrial, and photoreceptor-related pathways. This study identifies and maps retinopathy in MCI and AD patients, demonstrating the quantitative relationship with brain pathology and cognition, and may lead to reliable retinal biomarkers for noninvasive retinal screening and monitoring of AD.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s00401-023-02548-2.

          Related collections

          Most cited references127

          • Record: found
          • Abstract: not found
          • Article: not found

          "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

            In 2011, the National Institute on Aging and Alzheimer’s Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer’s disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer’s Association to update and unify the 2011 guidelines. This unifying update is labeled a “research framework” because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer’s Association Research Framework, Alzheimer’s disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six-stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker-based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker-based research should not be considered a template for all research into age-related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that β-amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              “Mini-mental state”

                Bookmark

                Author and article information

                Contributors
                maya.koronyo@csmc.edu
                Journal
                Acta Neuropathol
                Acta Neuropathol
                Acta Neuropathologica
                Springer Berlin Heidelberg (Berlin/Heidelberg )
                0001-6322
                1432-0533
                11 February 2023
                11 February 2023
                2023
                : 145
                : 4
                : 409-438
                Affiliations
                [1 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, , Cedars-Sinai Medical Center, ; 127 S. San Vicente Blvd., Los Angeles, CA 90048 USA
                [2 ]GRID grid.19006.3e, ISNI 0000 0000 9632 6718, Doheny Eye Institute, , University of California Los Angeles, ; Los Angeles, CA USA
                [3 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Biostatistics and Bioinformatics Research Center, , Cedars-Sinai Medical Center, ; Los Angeles, CA 90048 USA
                [4 ]GRID grid.42505.36, ISNI 0000 0001 2156 6853, Norris Comprehensive Cancer Center, Keck School of Medicine, , University of Southern California, ; Los Angeles, CA USA
                [5 ]GRID grid.1003.2, ISNI 0000 0000 9320 7537, Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, , The University of Queensland, ; Brisbane, QLD Australia
                [6 ]GRID grid.266093.8, ISNI 0000 0001 0668 7243, Institute for Memory Impairments and Neurological Disorders, , University of California, ; Irvine, CA USA
                [7 ]GRID grid.38142.3c, ISNI 000000041936754X, Department of Cell Biology, , Harvard Medical School, ; Boston, USA
                [8 ]GRID grid.1021.2, ISNI 0000 0001 0526 7079, School of Medicine, , Deakin University, ; Victoria, Australia
                [9 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Department of Biomedical Sciences and Eye Program, Board of Governors Regenerative Medicine Institute, , Cedars-Sinai Medical Center, ; Los Angeles, CA USA
                [10 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Departments of Neurology and Biomedical Sciences, Division of Applied Cell Biology and Physiology, , Cedars-Sinai Medical Center, ; 127 S. San Vicente Blvd., Los Angeles, CA USA
                [11 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Barbra Streisand Women’s Heart Center, , Cedars-Sinai Medical Center, ; Los Angeles, CA USA
                [12 ]GRID grid.50956.3f, ISNI 0000 0001 2152 9905, Department of Medicine, , Cedars-Sinai Medical Center, ; Los Angeles, CA USA
                [13 ]GRID grid.1013.3, ISNI 0000 0004 1936 834X, Save Sight Institute, , University of Sydney, ; Sydney, NSW Australia
                [14 ]GRID grid.1004.5, ISNI 0000 0001 2158 5405, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, , Macquarie University, ; Sydney, NSW Australia
                [15 ]GRID grid.42505.36, ISNI 0000 0001 2156 6853, Department of Neurology, , Keck School of Medicine of USC, ; Los Angeles, CA USA
                [16 ]GRID grid.42505.36, ISNI 0000 0001 2156 6853, Departments of Pathology and Ophthalmology, Keck School of Medicine, USC Roski Eye Institute, , University of Southern California, ; Los Angeles, CA USA
                [17 ]GRID grid.42505.36, ISNI 0000 0001 2156 6853, Department of Pathology Program in Neuroscience, Keck School of Medicine, , University of Southern California, ; Los Angeles, CA USA
                [18 ]GRID grid.418911.4, European Brain Research Institute (EBRI), ; Viale Regina Elena, Rome, Italy
                Author information
                http://orcid.org/0000-0003-2864-8442
                Article
                2548
                10.1007/s00401-023-02548-2
                10020290
                36773106
                02682a4c-8659-40df-babf-3a870d4b34f6
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 7 October 2022
                : 2 February 2023
                : 3 February 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000049, National Institute on Aging;
                Award ID: R01AG056478
                Award ID: R01AG055865
                Award ID: AG056478-04S1
                Award ID: R01AG062007
                Award Recipient :
                Funded by: The Haim Saban foundation
                Funded by: The Maurice Marciano foundation
                Funded by: The Tom Gordon foundation
                Funded by: National Institute of Health
                Award ID: R01EY013431
                Award ID: R01GM132129
                Award Recipient :
                Funded by: Cedars-Sinai Medical Library
                Categories
                Original Paper
                Custom metadata
                © Springer-Verlag GmbH Germany, part of Springer Nature 2023

                Neurology
                ocular abnormalities,eye,neurodegenerative disorders,s100β,gfap,iba1,scfva13-intraneuronal oligomers,immune responses

                Comments

                Comment on this article